A5040504042- Acute Myeloid Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Protein Degradation and Inhibitors
- Sports Performance and Training
- Cell death mechanisms and regulation
- Virus-based gene therapy research
- Chronic Myeloid Leukemia Treatments
- 3D Printing in Biomedical Research
- Biochemical and Molecular Research
- Animal Virus Infections Studies
- Interprofessional Education and Collaboration
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Influenza Virus Research Studies
- Health Sciences Research and Education
- Plant Disease Resistance and Genetics
- interferon and immune responses
- Cancer-related Molecular Pathways
- Exercise and Physiological Responses
- Acute Lymphoblastic Leukemia research
- Winter Sports Injuries and Performance
- Metal complexes synthesis and properties
Wayne State University
2020-2025
Campbell University
2021-2022
National Institutes of Health
2018
National Cancer Institute
2017-2018
Michigan State University
2015-2016
Colorado State University
2003
Abstract Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset cell lines and primary patient samples, particularly stem cells, while producing negligible toxicity normal hematopoietic cells. suppressed mitochondrial respiration elevated α-ketoglutarate by suppressing dehydrogenase (αKGDH)...
Abstract Recombination nodules (RNs) are closely correlated with crossing over, and, because they observed by electron microscopy of synaptonemal complexes (SCs) in extended pachytene chromosomes, RNs provide the highest-resolution cytological marker currently available for defining frequency and distribution crossovers along length chromosomes. Using maize inbred line KYS, we prepared an SC karyotype which each was identified relative arm ratio related to proper linkage group using...
Abstract Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and salvage therapy relapsed/refractory who have been treated with intensive chemotherapy. While this an important option, many fail to achieve complete remission of those that do, majority relapse. Leukemia stem cells (LSCs) are believed be responsible AML relapse can targeted through oxidative phosphorylation reduction. We previously reported ONC213 disrupts decreases...
Targeting oxidative phosphorylation (OXPHOS) is a promising strategy to improve treatment outcomes of acute myeloid leukemia (AML) patients. IACS-010759 mitochondrial complex I inhibitor that has demonstrated preclinical antileukemic activity and being tested in Phase clinical trials. However, deficiency been reported inhibit apoptotic cell death through prevention cytochrome c release. Thus, combining with BH3 mimetic may overcome this mechanism resistance leading synergistic against AML....
Influenza is one of the most important infectious diseases in humans. The best way to prevent severe illness caused by influenza infection vaccination. Cell culture-derived vaccines are being considered addition widely used egg-based system order support increasing seasonal demand and be prepared case a pandemic. culture based systems offer increased safety, capacity, flexibility with reduced downstream processing relative embryonated eggs. We have previously reported chick embryo cell line,...
FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3-ITD) mutations occur in about 25% of all acute myeloid leukemia (AML) patients and confer a poor prognosis. FLT3 inhibitors have been developed to treat with FLT3-mutated AML shown promise, though the acquisition resistance occurs, highlighting need for combination therapies prolong response inhibitors. In this study, we investigated selective Mcl-1 inhibitor AZD5991 gilteritinib MRX-2843. The combinations synergistically...
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) patients who are over the age of 75 cannot tolerate standard chemotherapy. Despite high response rates these therapies, most succumb disease due relapse and/or drug resistance, providing an unmet clinical need for novel therapies improve AML patient survival. ME-344 potent isoflavone demonstrated inhibitory activity toward oxidative...
<b>Abstract ID 95704</b> <b>Poster Board 261</b> Acute myeloid leukemia (AML) overall survival rates remain unacceptably low. Hence, new drugs are needed to improve survival. The imipridone family of anticancer agents have shown efficacy against various cancers, including AML. Thus, we investigated the and mechanism action novel imipridone, ONC213, in preclinical AML models. cell lines primary patient samples showed varying degrees sensitivity ONC213. However, ONC213 uniformly suppressed...
<p>THP-1 metabolomics data</p>
<p>Supplementary Figure S5</p>
<p>Supplementary Figure S7</p>
<p>THP-1 metabolomics data</p>
<p>Patient characteristics for AML cell lines</p>
<p>Patient characteristics of primary AML patient samples</p>
<p>Supplementary Figure S7</p>
<p>Supplementary Figure S1</p>
<div>Abstract<p>Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset cell lines and primary patient samples, particularly stem cells, while producing negligible toxicity normal hematopoietic cells. suppressed mitochondrial respiration elevated α-ketoglutarate by suppressing...